Markers of thrombophilia in patients with retinal vein thrombosis;Determinación de factores trombofílicos en pacientes con trombosis venosas retinianas

Revista Medica de Chile

Volumn 133, Issue 2, 2005, Pages 167-174

  Traipe C, Leonidas ^a,b   Conte L, Guillermo ^a   Conte S, Francisco J ^b   Ibáñez L, Santiago ^b   Meza R, Patricio ^a   Rojas U, Basilio ^b   Cuneo V, Marianela ^a   Verdaguer T, Juan ^b  

^a HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^b Fundacion Oftalmologica Los Andes   (Chile)

Author keywords

Activated protein C resistance; Antiphospholipid syndrome; Retinal vein occlusion; Thrombophilia

Indexed keywords

BIOLOGICAL MARKER;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTICLE; BLOOD; BLOOD CLOTTING TEST; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; PROTEIN S DEFICIENCY; RETINA VEIN OCCLUSION; RISK FACTOR; SEX RATIO; THROMBOPHILIA;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD COAGULATION TESTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN S DEFICIENCY; RETINAL VEIN OCCLUSION; RISK FACTORS; SEX DISTRIBUTION; THROMBOPHILIA;

EID: 27744553856     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. PRISCO D, MARCUCA R. Retinal vein trombosis: risks factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 2002; 32: 308-11.
2. HAYREH SS, ZIMMERMAN B, MC CARTHY MJ, PODHAJSKY P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131: 61-77.
3. FONG A, SCHATZ H. Central retinal vein occlusion in young adults. Surv Ophthalmol 1993; 37: 393-417.
4. AREND O, REMKY A, JUNG F, KIESEWETTER H, REIM M, WOLF S. Role of rheologic factors in patients with acute central retinal vein occlusion. Ophthalmology 1996; 103: 80-6.
5. BERNARD AG, CHANABAL A, LE LONG F. Elevated erythrocyte aggregation in patients with central retinal vein occlusion and without conventional risk factors. Ophthalmology 1994; 101: 1483-7.
6. THE EYE DISEASE CASE-CONTROL STUDY GROUP. Risks factors for central retinal vein occlusion. Arch Ophthalmol 1996; 114: 545-54.
7. RATH E, FRANCK R, SHIN D, KIM CH. Risks factors for retinal vein occlusions: a case control study. Ophthalmology 1992; 99: 509-14.
8. THE CENTRAL VEIN OCCLUSION STUDY GROUP. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997; 115: 486-91.
9. KLEINER RC, NAJARIAN LV, SCHATTEN S, JABS DA, PATZ A, KAPLAN HJ. Vaso-occlusive retinopathy associated with anti-phospholipid antibodies (lupus anti-coagulant retinopathy). Ophthalmology 1989; 896-904.
10. COBO-SORIANO R, SÁNCHEZ-RAMÓN S, APARICIO MJ, TEIJEIRO MA, VIDAL P, SUÁREZ-LEOZ M ET AL. Anti-phospholipid antibodies and retinal thrombosis in patients without risk factors: a prospective case-control study. Am J Ophthamol 1999; 128: 725-32.
11. WIEHENS B, SCHRODER J, POTZSCH B, ROCHELS R. Primary antiphospholipid antibody syndrome and retinal occlusive vasculopathy. Am J Ophthalmol 1997; 123: 848-50.
12. GLACET-BERNARD A, BAYANI N, CHRETIEN P, COCHARD C, LELONG F, COSCAS G. Antiphospholipid antibodies in retinal vascular occlusions. Arch Opthalmol 1994; 112: 790-5.
13. CROWTHER MA, KELTON JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification. Ann Intern Med 2002; 138: 128-34.
14. BAUER KA. The trombophilias: well defined risks factors with uncertain therapeutics implications. Ann Intern Med 2001; 135: 367-73.
15. CHAK M, WALLACE GR, GRAHAM EM, STANFORD MR. Thrombophilia: genetic polymorphisms and their association with retinal vascular occlusive disease. Br J Ophthalmol 2001; 85: 883-6.
16. HANSEN L, KRISTENSEN HL, BEK T, INGERSLEV J. Markers of thrombophilia in retinal vein thrombosis. Acta Ophthalmol Scand 2000; 78: 523-8.
17. GREVEN CM, WEABER RG, OWEN J. Protein S deficiency and bilateral branch retinal artery occlusion. Ophthalmology 1991; 98: 33-4.
18. GREINER K, HAFNER G, DICK B, PEETZ D, PRELLWITZ W. Retinal vascular occlusion and deficiencies in the protein C pathway. Am J Ophthalmol 1999; 128: 69-74.
19. PEREIRA J, QUIROGA T, GOYCOLEA M, HIDALGO P, KALTWASSER G, MEZZANO D. Resistencia a la proteína C activada: estudio de laboratorio y prevalencia del defecto en la población chilena. Rev Méd Chile 1996; 124: 663-8.
20. LARSSON J, HILLARP A, OLAFSDOTTIR E, BAUER B. Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. Acta Ophthalmol Scand 1999; 77: 634-7.
21. JOHNSON MT, EL-DEFRAWY S, HODGE WG, LEONARD BC, KERTES PJ, TAYLOR S ET AL. Prevalence of factor V Leiden and activated protein C resistance in central retinal vein occlusion. Retina 2001; 21: 161-6.
22. CIARDELLA AP, YANUZZI LA, FREUND KB, DIMICHELLE D, NEJAT M, DE ROSA J. Factor V Leiden, activated protein C resistance and retinal vein occlusion. Retina 1998; 18: 308-15.
23. INCORVAIA C, LAMBERTI G, PARMEGGIANI F, FERRARESI P, CAIZOLARI E, BERNARDI F ET AL. Idiophatic central retinal vein occlusion in a thrombophilic patient with the heterozygous 20210 G/A prothrombin genotype. Am J Ophthalmol 1999; 128: 247-8.
24. BOYD S, OWENS D, GIN T, BUNCE K, SHERAFAT H, PERRY D ET AL. Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol 2001; 85: 1313-5.
25. GLUECK CH, BELL H, VADLAMANI L, GUPTA A, FONTAINE R, WANG P. Heritable thrombophilia and hypofibrinolysis: possible causes of retinal vein occlusion. Arch Ophthalmol 1999; 117: 43-9.
26. LIP P, BLANN AD, JONES AF, LIP G. Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. Eye 1998; 12: 245-51.
27. VAN TIEBURG NH, ROSENDAL FR, BERTINA RM. Thrombin activable fibrinolysis inhibitor and the risk for deep vein trombosis. Blood 200??; 95: 2855-9.
28. PIANKA P, ALMONG Y, MAN O, GOLDSTEIN M, SEAL B, LOEWENSTIEN A. Hyperhomocysteinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. Ophthalmology 2000; 107: 1588-92.
29. CAHILL M, KARABATZKI M, MELEADY R, REFSUM H, UELAND P. Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol 2000; 84: 154-7.
30. JACQUES PF, BOSTOM AG, WILLIAMS RR, ELLISON RC, ECKFELDT JH. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
31. WENZLER EM, RADEMAKERS A, BOERS G, CRUYSBERG J, WEBERS CA. Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am J Ophthalmol 1993; 115: 162-7.
32. JUHAN-VAGUE I, ALESSI MC, MAVRI A, MORANGE PE. Plasminogen activator inhibitor-1, inflammation, obesity, insuline resistance and vascular risk. J Thromb Haemost 2003; 1: 1575-9.
33. MILLS JD, GRANT PT. Insuline resistance, haemostatic factors and cardiovascular risk. Br J Diabetes Vasc Dis 2002; 2: 19-26.
34. FONG AC, SCHATZ H, MC DONALD HR, BURTON TC, MABERLEY AL, JOFFE L. Central retinal vein occlusion in young adults (papillophlebitis). Retina 1992; 12: 3-11.
35. VINE AK, SAMAMA MM. Screening for resistance to activated protein C and the mutant gene for factor V: Q506 in patients with central retinal vein occlusion. Am J Ophthalmol 1997; 124: 673-6.
36. GOTTLIEB JL, BLICE JP, MESTICHELLI B. Activated protein C resistance, factor V leiden, and central retinal vein occlusion in young adults. Arch Ophthalmol 1998; 116: 577-9.
37. BANDELLO F, D'ANGELO S, PARLAVECCHIA M, TAVOLA A, DELLA VALLE P, BRANCATO R ET AL. Hypercoagulability and high lipoprotein (a) levels in patients with central retinal vein occlusion. Thromb Haemost 1994; 72: 39-43.
38. MANUCCI PM. The meassurement of multifactorial thrombophilia. Thromb Haemost 2002; 88: 1-2.